Cipher Pharmaceuticals (OTCMKTS:CPHRF – Get Free Report) (TSE:CPH) is expected to be issuing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.1550 per share and revenue of $17.1360 million for the quarter.
Cipher Pharmaceuticals Stock Performance
Shares of Cipher Pharmaceuticals stock opened at $10.95 on Thursday. The company’s 50 day moving average is $10.89 and its 200 day moving average is $10.79. Cipher Pharmaceuticals has a twelve month low of $6.63 and a twelve month high of $12.50.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America.
In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
